Real-time US stock institutional ownership tracking and fund flow analysis to understand who owns and is buying the stock. We monitor 13F filings and institutional buying patterns because large investors often have superior information.
BioCryst shares have experienced notable weakness in recent trading sessions, with the stock declining 4% in the latest period to trade near $9.19. The move comes amid a broader pullback across small-cap biotechnology names, as sector sentiment remains sensitive to both clinical-stage pipeline updat
BioCryst (BCRX) Slides -4.02% as Selling Pressure Mounts 2026-05-15 - Dividend Growth
BCRX - Stock Analysis
3455 Comments
1401 Likes
1
Nyomii
Elite Member
2 hours ago
This feels like the beginning of a problem.
👍 33
Reply
2
Amiyaah
Power User
5 hours ago
Free US stock correlation to major indices and sector benchmarks for performance attribution analysis. We help you understand how your portfolio moves relative to broader market benchmarks.
👍 230
Reply
3
Chiziterem
Insight Reader
1 day ago
A retracement could provide a better entry point for long-term investors.
👍 136
Reply
4
Rashonna
Power User
1 day ago
Access real-time US stock market updates and expert-curated picks focused on consistent returns, strong fundamentals, and disciplined risk management strategies. We deliver daily analysis and strategic recommendations to empower your investment decisions and build long-term wealth.
👍 26
Reply
5
Jovaniel
Experienced Member
2 days ago
That made me do a double-take. 👀
👍 133
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.